Related Experiment Videos
Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo
1Analytical and Metabolic Research Laboratories, Sankyo Company, Ltd., Japan.
Abstract:
RS-1541 is a 13-O-palmitoyl derivative of rhizoxin, an inhibitor of tubulin polymerization. After intravenous administration of RS-1541 to mice bearing M5076 sarcoma, the maximal inhibitory effect of RS-1541 on DNA synthesis in the tumor was observed 24 h after administration, in agreement with the Cmax of rhizoxin produced from RS-1541, but not with the Cmax of RS-1541. The inhibitory effect after RS-1541 was much higher than that after rhizoxin itself. In the spleen, thymus and bone marrow, DNA synthesis was strongly inhibited by rhizoxin but not by RS-1541. After administration of RS-1541, no significant amounts of rhizoxin were detected in the tissues, except for the tumor. In acute toxicity tests, RS-1541 appeared to be less toxic than rhizoxin. These results indicate that RS-1541 possesses a high tumor-selective effect compared with rhizoxin, because of the selective production of rhizoxin in the tumor after administration of RS-1541.
Insights
RS-1541, a rhizoxin derivative, shows enhanced tumor-selective inhibition of DNA synthesis by producing rhizoxin primarily in tumors. This novel compound is less toxic than rhizoxin, offering a promising cancer therapy approach.
Area of Science:
- Pharmacology
- Oncology
- Medicinal Chemistry
Background:
- Rhizoxin is a potent tubulin polymerization inhibitor with anticancer potential.
- Developing derivatives of rhizoxin can improve its therapeutic index and tumor selectivity.
- RS-1541 is a novel 13-O-palmitoyl derivative of rhizoxin.
Purpose of the Study:
- To evaluate the efficacy and tumor selectivity of RS-1541 compared to rhizoxin.
- To investigate the pharmacokinetic profile and mechanism of action of RS-1541.
- To assess the toxicity profile of RS-1541 in preclinical models.
Main Methods:
- Intravenous administration of RS-1541 and rhizoxin to mice bearing M5076 sarcoma.
- Measurement of DNA synthesis inhibition in tumor and healthy tissues (spleen, thymus, bone marrow).
- Quantification of rhizoxin levels in tissues after RS-1541 administration.
- Acute toxicity testing of RS-1541 and rhizoxin.
Main Results:
- RS-1541 administration led to maximal tumor DNA synthesis inhibition at 24 hours, correlating with rhizoxin Cmax, not RS-1541 Cmax.
- RS-1541 demonstrated significantly higher tumor inhibitory effects compared to rhizoxin.
- DNA synthesis in spleen, thymus, and bone marrow was not significantly inhibited by RS-1541, unlike rhizoxin.
- Rhizoxin was selectively detected in tumor tissue after RS-1541 administration.
- RS-1541 exhibited lower acute toxicity than rhizoxin.
Conclusions:
- RS-1541 exhibits superior tumor selectivity compared to rhizoxin.
- Selective production of rhizoxin within the tumor microenvironment underlies RS-1541's enhanced efficacy and reduced systemic toxicity.
- RS-1541 represents a promising prodrug strategy for targeted cancer therapy.